Fingolimod-associated macular edema: Incidence, detection, and management

Neurology

Volumn 78, Issue 9, 2012, Pages 672-680

  Jain, Nieraj ^a   Bhatti, M Tariq ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; PLACEBO;

DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG INDICATION; DRUG WITHDRAWAL; EYE EXAMINATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; MULTIPLE SCLEROSIS; NEUROLOGIST; OPTIC NEURITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; RETINA MACULA EDEMA; REVIEW; UVEITIS;

EID: 84858257726     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318248deea     Document Type: Review

References (41)

1. Cunha-Vaz JG, Shakib M, Ashton N. Studies on the permeability of the blood-retinal barrier: I: on the existence, development, and site of a blood-retinal barrier. Br J Ophthalmol 1966;50:441- 453.
2. Hudspeth AJ, Yee AG. The intercellular junctional complexes of retinal pigment epithelia. Invest Ophthalmol 1973;12:354 -365.
3. Miller SS, Steinberg RH. Active transport of ions across frog retinal pigment epithelium. Exp Eye Res 1977;25:235-248. (Pubitemid 8204209)
4. Complications of cataract surgery. In: Lens and Cataract. San Francisco: American Academy of Ophthalmology;2008:193-194.
5. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024 - 1029.
6. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315-320. (Pubitemid 8335892)
7. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidinediones. Diabet Med 2008;25:860 - 862.
8. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F 3rd. Detection of diabetic macular edema: ophthalmoscopy versus photography-Early Treatment Diabetic Retinopathy Study Report Number 5: the ETDRS Research Group. Ophthalmology 1989;96:746 -750; discussion 750-751.
9. Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 2004;137:156 -169.
10. Wojtkowski M, Srinivasan V, Fujimoto JG, et al. Three-dimensional retinal imaging with high-speed ultrahighresolution optical coherence tomography. Ophthalmology 2005;112:1734 -1746.
11. Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 2006;124:193-198. (Pubitemid 43247068)
12. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004; 122:330 -335.
13. Antcliff RJ, Stanford MR, Chauhan DS, et al. Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoid macular edema in patients with uveitis. Ophthalmology 2000;107:593-599. (Pubitemid 30191384)
14. Ali F. A review of diabetic macular edema. Available at: http://www.djo.harvard.edu/site.php?url=/physicians/oa/387. Accessed June 5, 2011.
15. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796 -1806.
16. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346 -349.
17. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
18. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689 -701.
19. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301-312. (Pubitemid 29519909)
20. Tauseef M, Kini V, Knezevic N, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1- phosphate receptor signaling in endothelial cells. Circ Res 2008;103:1164 -1172.
21. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004;170:987-993. (Pubitemid 39425695)
22. Peng X, Hassoun PM, Sammani S, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004;169:1245-1251. (Pubitemid 38680403)
23. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006;2:434-441. (Pubitemid 44114922)
24. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 2009;77:39-45.
25. Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004;279:24692-24700. (Pubitemid 38725337)
26. Lee JF, Zeng Q, Ozaki H, et al. Dual roles of tight junction-associated protein, zonula occludens-1, in sphin-gosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem 2006;281:29190 -29200.
27. Paik JH, Skoura A, Chae SS, et al. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 2004;18:2392-2403. (Pubitemid 39304686)
28. de Oliveira F. Pericytes in diabetic retinopathy. Br J Ophthalmol 1966;50:134 -143.
29. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402- 415.
30. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387- 401.
31. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6:2912-2921.
32. Fingolimod (NDA 22-527) background package. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/peripheralandcentral nervoussystemdrugsadvisorycommittee/ucm214670.pdf. Accessed May 15, 2011.
33. Zarbin M, Reder A, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis (MS) (suppl 4:P03.208). Presented at the American Academy of Neurology annual meeting. Honolulu, HI, 2011.
34. NDA 22-527. Available at: http://www.fda.gov/down loads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ PeripheralandCentralNervousSystemDrugsAdvisory Committee/UCM216553.pdf. Accessed May 15, 2011.
35. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 1999;52:179 -181.
36. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993;100:818-824.
37. Gilenya full prescribing information. Available at: http:// www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed May 14, 2011.
38. Abou Zeid N, Bhatti MT. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations. Neurologist 2008;14:207-223.
39. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: The Optic Neuritis Study Group. N Engl J Med 1992;326:581-588.
40. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124 -1140.
41. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82:1689 -1697.